Cargando…
Rechallenge pemetrexed-based chemotherapy provides an option for initially benefited patients with advanced lung adenocarcinoma
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440023/ https://www.ncbi.nlm.nih.gov/pubmed/34133351 http://dx.doi.org/10.1097/CM9.0000000000001511 |
| _version_ | 1783752627083804672 |
|---|---|
| author | Wang, Jia-Ni Qiao, Quan-Hui Hu, Xing-Sheng Liu, Yu-Tao Wang, Zhi-Jie Duan, Jian-Chun Feng, Yu Zhu, Hao-Hua |
| author_facet | Wang, Jia-Ni Qiao, Quan-Hui Hu, Xing-Sheng Liu, Yu-Tao Wang, Zhi-Jie Duan, Jian-Chun Feng, Yu Zhu, Hao-Hua |
| author_sort | Wang, Jia-Ni |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8440023 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84400232021-09-20 Rechallenge pemetrexed-based chemotherapy provides an option for initially benefited patients with advanced lung adenocarcinoma Wang, Jia-Ni Qiao, Quan-Hui Hu, Xing-Sheng Liu, Yu-Tao Wang, Zhi-Jie Duan, Jian-Chun Feng, Yu Zhu, Hao-Hua Chin Med J (Engl) Correspondence Lippincott Williams & Wilkins 2021-09-05 2021-06-16 /pmc/articles/PMC8440023/ /pubmed/34133351 http://dx.doi.org/10.1097/CM9.0000000000001511 Text en Copyright © 2021 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
| spellingShingle | Correspondence Wang, Jia-Ni Qiao, Quan-Hui Hu, Xing-Sheng Liu, Yu-Tao Wang, Zhi-Jie Duan, Jian-Chun Feng, Yu Zhu, Hao-Hua Rechallenge pemetrexed-based chemotherapy provides an option for initially benefited patients with advanced lung adenocarcinoma |
| title | Rechallenge pemetrexed-based chemotherapy provides an option for initially benefited patients with advanced lung adenocarcinoma |
| title_full | Rechallenge pemetrexed-based chemotherapy provides an option for initially benefited patients with advanced lung adenocarcinoma |
| title_fullStr | Rechallenge pemetrexed-based chemotherapy provides an option for initially benefited patients with advanced lung adenocarcinoma |
| title_full_unstemmed | Rechallenge pemetrexed-based chemotherapy provides an option for initially benefited patients with advanced lung adenocarcinoma |
| title_short | Rechallenge pemetrexed-based chemotherapy provides an option for initially benefited patients with advanced lung adenocarcinoma |
| title_sort | rechallenge pemetrexed-based chemotherapy provides an option for initially benefited patients with advanced lung adenocarcinoma |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440023/ https://www.ncbi.nlm.nih.gov/pubmed/34133351 http://dx.doi.org/10.1097/CM9.0000000000001511 |
| work_keys_str_mv | AT wangjiani rechallengepemetrexedbasedchemotherapyprovidesanoptionforinitiallybenefitedpatientswithadvancedlungadenocarcinoma AT qiaoquanhui rechallengepemetrexedbasedchemotherapyprovidesanoptionforinitiallybenefitedpatientswithadvancedlungadenocarcinoma AT huxingsheng rechallengepemetrexedbasedchemotherapyprovidesanoptionforinitiallybenefitedpatientswithadvancedlungadenocarcinoma AT liuyutao rechallengepemetrexedbasedchemotherapyprovidesanoptionforinitiallybenefitedpatientswithadvancedlungadenocarcinoma AT wangzhijie rechallengepemetrexedbasedchemotherapyprovidesanoptionforinitiallybenefitedpatientswithadvancedlungadenocarcinoma AT duanjianchun rechallengepemetrexedbasedchemotherapyprovidesanoptionforinitiallybenefitedpatientswithadvancedlungadenocarcinoma AT fengyu rechallengepemetrexedbasedchemotherapyprovidesanoptionforinitiallybenefitedpatientswithadvancedlungadenocarcinoma AT zhuhaohua rechallengepemetrexedbasedchemotherapyprovidesanoptionforinitiallybenefitedpatientswithadvancedlungadenocarcinoma |